Andrew Jablonski – Short Bowel Patient & Expert Advocate

An Compassionate Leader in the Fight Against Short Bowel Syndrome

Mr. Andrew (Andy) E. Jablonski is the visionary Founder and Executive Director of the Short Bowel Syndrome Foundation, Inc. (SBSF), a distinguished 501©(3) public charity headquartered in Lincoln, NE. His unwavering commitment to making a positive impact drives SBSF’s mission: providing crucial support to individuals, caregivers, and healthcare providers affected by the rare intestinal disease known as Short Bowel Syndrome (SBS).

Educational Journey and Leadership:

  • A graduate of Southeast Community College with a degree in Entrepreneurship, Jablonski furthered his education at Doane University. There, he earned a Bachelor of Arts in Human Relations, specializing in mental health and counseling.
  • Leveraging this comprehensive educational background, Jablonski oversees the day-to-day operations of SBSF, ensuring seamless functioning and impactful outcomes.

Community Engagement and Advocacy:

  • Beyond his pivotal role at SBSF, Jablonski has left an indelible mark as a Patient and Physician Advisor at NPS, NAIA, and Shire Pharmaceuticals from 2011 to 2017.
  • He actively manages multiple online support groups, fostering a sense of community and understanding among those affected by Short Bowel Syndrome.
  • Jablonski is an enthusiastic public speaker, amplifying awareness and understanding of SBS through engaging discourse.

Rare Disease Industry Expertise:

  • With over 13 years of experience, Andrew (Andy) Jablonski is a passionate and skilled leader.
  • As the founder and executive director of SBSF, he leverages personal and professional expertise to provide comprehensive support and advocacy to patients and their families within the SBS community.
  • Jablonski’s impact extends beyond SBSF. He serves as a patient and physician communications advisor at Naia Pharmaceuticals and NPS Pharma, facilitating dialogue and collaboration with stakeholders who treat SBS and other gastrointestinal disorders.
  • His instrumental role in advancing novel therapies for SBS, including Gattex®, has earned him recognition as one of the most influential figures in orphan drugs.

Andrew Jablonski’s mission is clear: to improve the quality of life and outcomes for those affected by these rare and challenging conditions. His compassionate leadership inspires hope and resilience within the SBS community.